Aerie Pharmaceuticals Inc (NASDAQ:AERI) has been assigned a $100.00 price target by research analysts at Cowen and Company in a research note issued to investors on Friday. The brokerage presently has a “buy” rating on the stock. Cowen and Company’s target price points to a potential upside of 78.89% from the stock’s current price.

Other analysts have also issued reports about the company. Cantor Fitzgerald set a $56.00 target price on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, April 12th. Aegis reiterated a “buy” rating and issued a $63.00 price target on shares of Aerie Pharmaceuticals in a research note on Thursday, April 13th. Stifel Nicolaus lifted their price target on Aerie Pharmaceuticals from $55.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, April 6th. Canaccord Genuity set a $50.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, March 1st. Finally, Roth Capital assumed coverage on Aerie Pharmaceuticals in a research note on Friday, February 17th. They issued a “buy” rating and a $69.00 price target for the company. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $61.00.

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals (NASDAQ:AERI) opened at 55.90 on Friday. The firm’s market capitalization is $1.88 billion. Aerie Pharmaceuticals has a 52-week low of $16.41 and a 52-week high of $59.50. The stock’s 50 day moving average price is $42.29 and its 200 day moving average price is $42.46.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Tuesday, May 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.74) by $0.02. Analysts expect that Aerie Pharmaceuticals will post ($2.59) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This article was first posted by American Banking News and is the property of of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/05/27/aerie-pharmaceuticals-inc-aeri-given-a-100-00-price-target-by-cowen-and-company-analysts.html.

In other Aerie Pharmaceuticals news, Director Gerald D. Cagle acquired 2,000 shares of Aerie Pharmaceuticals stock in a transaction dated Wednesday, April 19th. The stock was acquired at an average cost of $41.70 per share, for a total transaction of $83,400.00. Following the completion of the transaction, the director now owns 10,900 shares in the company, valued at approximately $454,530. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 8.77% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Jennison Associates boosted its stake in shares of Aerie Pharmaceuticals by 21.6% in the third quarter. Jennison Associates now owns 3,764,019 shares of the company’s stock valued at $66,774,000 after buying an additional 669,110 shares during the last quarter. California State Teachers Retirement System boosted its stake in shares of Aerie Pharmaceuticals by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 37,966 shares of the company’s stock valued at $924,000 after buying an additional 600 shares during the last quarter. Convector Capital Management LP purchased a new stake in shares of Aerie Pharmaceuticals during the fourth quarter valued at approximately $1,875,000. State Street Corp boosted its stake in shares of Aerie Pharmaceuticals by 36.9% in the fourth quarter. State Street Corp now owns 820,644 shares of the company’s stock valued at $31,059,000 after buying an additional 221,146 shares during the last quarter. Finally, Oxford Asset Management purchased a new stake in shares of Aerie Pharmaceuticals during the fourth quarter valued at approximately $1,840,000. Institutional investors and hedge funds own 95.69% of the company’s stock.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

12 Month Chart for NASDAQ:AERI

Receive News & Ratings for Aerie Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.